Why it matters: This article discusses a new study on the use of MDMA-assisted therapy for new mothers with opioid addiction and post-traumatic stress disorder (PTSD). The study aims to determine if MDMA, in combination with trauma-focused therapy, can help new mothers overcome their drug dependency and improve bonding with their infants.
What they are saying: Dr. Larry Leeman, the medical director of the University of New Mexico’s Milagro Program, is leading the study. He notes that New Mexico has been heavily affected by the opioid epidemic and hopes that MDMA-assisted therapy can help mothers overcome their trauma, reduce opioid use, and improve their ability to bond with their babies.
The big picture: The study, approved by the FDA, will enroll 15 participants with moderate to severe PTSD six to 12 months after giving birth. They will receive 12 weeks of intensive therapy and three medication sessions using MDMA. The project is funded through private donations and is a collaboration with the Multidisciplinary Association for Psychedelic Studies.
What to watch: The results of this pilot study could provide valuable insights into the effectiveness of MDMA-assisted therapy for addressing opioid addiction and PTSD in new mothers. If successful, it could pave the way for further research and potential therapeutic applications.
My take: The use of MDMA-assisted therapy for treating mental health conditions is a promising area of research. This study specifically focuses on addressing the intersecting challenges faced by new mothers dealing with opioid addiction and PTSD. If the results are positive, it could offer a new approach to support these mothers in their recovery and improve outcomes for both them and their infants. However, it is essential to proceed with caution, gathering more evidence and ensuring proper guidelines and regulations are in place to ensure the safety and effectiveness of these treatments.
